Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Foreign marketing data

This article was originally published in The Tan Sheet

Executive Summary

Conference report accompanying the Agriculture/FDA appropriations bill, which includes a $1.14 bil. budget for FDA in FY 2000, instructs the agency to submit a final rule under the "material-time/material-extent" standard within 60 days of signing the act. Initially expected to be published in June 1999, FDA decided to determine whether ingredients should be included in an OTC final monograph based on foreign marketing data separately from the sunscreen final monograph (1"The Tan Sheet," May 24, p. 4). The bill, HR 1906, which passed the House Oct. 1, is expected to be taken up by the Senate Oct. 12, at which time the foreign marketing issue will be discussed

You may also be interested in...



FDA appropriations

Agency to receive $1.18 bil. in FY 2000 under the Agriculture/FDA appropriations bill approved by the Senate by a 74-26 vote Oct. 13. The House passed the measure (HR 1906) Oct. 1. President Clinton has said he will sign the legislation. The funding marks a $69 mil. increase over the agency's fiscal year 1999 budget, but is well below the President's request of $1.35 bil. CDER will receive $309 mil.; the Administration had requested $316 mil. for the drugs center. CFSAN and related field activities will get $269.2 mil. The bill requires the agency to submit a final rule on the "material time/material extent" standard on the use of foreign marketing data for sunscreens 60 days after passage (1"The Tan Sheet" Oct. 11, In Brief)

FDA appropriations

Agency to receive $1.18 bil. in FY 2000 under the Agriculture/FDA appropriations bill approved by the Senate by a 74-26 vote Oct. 13. The House passed the measure (HR 1906) Oct. 1. President Clinton has said he will sign the legislation. The funding marks a $69 mil. increase over the agency's fiscal year 1999 budget, but is well below the President's request of $1.35 bil. CDER will receive $309 mil.; the Administration had requested $316 mil. for the drugs center. CFSAN and related field activities will get $269.2 mil. The bill requires the agency to submit a final rule on the "material time/material extent" standard on the use of foreign marketing data for sunscreens 60 days after passage (1"The Tan Sheet" Oct. 11, In Brief)

FDA appropriations

Agency to receive $1.18 bil. in FY 2000 under the Agriculture/FDA appropriations bill approved by the Senate by a 74-26 vote Oct. 13. The House passed the measure (HR 1906) Oct. 1. President Clinton has said he will sign the legislation. The funding marks a $69 mil. increase over the agency's fiscal year 1999 budget, but is well below the President's request of $1.35 bil. CDER will receive $309 mil.; the Administration had requested $316 mil. for the drugs center. CFSAN and related field activities will get $269.2 mil. The bill requires the agency to submit a final rule on the "material time/material extent" standard on the use of foreign marketing data for sunscreens 60 days after passage (1"The Tan Sheet" Oct. 11, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel